Skip to Content

Generic Delzicol Availability

Delzicol is a brand name of mesalamine, approved by the FDA in the following formulation(s):

DELZICOL (mesalamine - capsule, delayed release;oral)

  • Manufacturer: APIL
    Approval date: February 1, 2013
    Strength(s): 400MG [RLD]

Has a generic version of Delzicol been approved?

No. There is currently no therapeutically equivalent version of Delzicol available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Delzicol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups
    Patent 6,649,180
    Issued: November 18, 2003
    Inventor(s): Seinosuke; Matsuura & Masaru; Tanjoh
    Assignee(s): Shionogi Qualicaps Co., Ltd.

    A cellulose ether film is formed of a composition comprising a cellulose ether as a base in which some of the hydrogen atoms of cellulosic hydroxyl groups are replaced by alkyl groups and/or hydroxyalkyl groups, a gelling agent, and a gelling aid. The total content of alkoxyl and hydroxyalkoxyl groups in the cellulose ether is limited to 23-37.6% by weight, which is effective for preventing the gelling aid from precipitating out and maintaining a favorable outer appearance during long-term storage.

    Patent expiration dates:

    • April 13, 2020
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.